Grit Bio secures funding for development of TIL therapies

By The Science Advisory Board staff writers

July 16, 2021 -- Grit Bio has secured a round of financing that it plans to use to develop tumor-infiltrating lymphocyte (TIL) therapies. The funding amount was not disclosed.

The series A+ financing round was led by GL Ventures of Hillhouse Group, with participation by Apricot Capital and Junshi Biosciences.

Founded in 2019, Grit Bio plans to bring the first TIL therapy for solid tumors to patients in China. Its leading candidate, GT101, is being tested in clinical trials.

The company is using three technology platforms to develop the therapy: its Stable Virus Producing Cell Line (StaViral) for T-cell editing; its Immunueregulatory Target Finder (ImmuT Finder) for identifying T-cell optimization targets; and its Stemness TIL Expansion Technology (StemTexp) for making TIL into an effective cell therapy product, it said.

MD Anderson, Refuge to develop next-gen cell therapies
The University of Texas MD Anderson Cancer Center is partnering with Refuge Biotechnologies to advance new cell therapies for the potential treatment...
Phio, AgonOx partner on T cell-based cancer immunotherapies
Phio Pharmaceuticals and AgonOx have announced a partnership to develop T cell-based cancer immunotherapies.

Copyright © 2021 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter